Evidence map›Paper›PMID 42068253›Full record

ArticleThe FEBS journal2026

Unraveling in vitro phase separation and aggregation properties of the structured region of FMRP and the impact of Fragile X syndrome-linked mutations.

Flavia Catalano, Alessandra Bigi, Francesca Troilo, Federica Gabriele, Gianluca Pistoia, Italia A Asteriti, Francesco Angelucci, Giorgio Giardina, Fabrizio Chiti, Carlo Travaglini-Allocatelli and 1 more

Abstract read
In one paragraph

Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Flavia CatalanoInstitute of Molecular Biology and Pathology National Research Council of Italy, Rome, Italy.
Alessandra BigiDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy.ORCID https://orcid.org/0000-0002-1067-6288
Francesca TroiloInstitute of Molecular Biology and Pathology National Research Council of Italy, Rome, Italy.
Federica GabrieleDepartment of Health, Life and Environmental Sciences, University of L'Aquila, Italy.
Gianluca PistoiaDepartment of Biochemical Sciences "A Rossi Fanelli", Sapienza, University of Rome, Italy.
Italia A AsteritiInstitute of Molecular Biology and Pathology National Research Council of Italy, Rome, Italy.
Francesco AngelucciDepartment of Health, Life and Environmental Sciences, University of L'Aquila, Italy.
Giorgio GiardinaDepartment of Biochemical Sciences "A Rossi Fanelli", Sapienza, University of Rome, Italy.ORCID https://orcid.org/0000-0002-0802-1370
Fabrizio ChitiDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy.ORCID https://orcid.org/0000-0002-1330-1289
Carlo Travaglini-AllocatelliDepartment of Biochemical Sciences "A Rossi Fanelli", Sapienza, University of Rome, Italy.ORCID https://orcid.org/0000-0001-8735-1126
Adele Di MatteoInstitute of Molecular Biology and Pathology National Research Council of Italy, Rome, Italy.ORCID https://orcid.org/0000-0002-5921-7365

Funding

ITACA.SB "Potentiating the Italian Capacity for Structural Biology Services in Instruct-ERIC IR0000009Progetto Dipartimenti di Eccellenza 2022-2027- Università di FirenzeRICATEN - Fondi di Ateneo 2023 Università di Firenze
6 · The paper itself

Abstract

Fragile X messenger ribonucleoprotein 1 (FMRP) is a multidomain RNA-binding protein highly expressed in neurons. It comprises a structured N-terminal region (NTR) containing five RNA/protein interaction domains and a large intrinsically disordered C-terminal region. A limited number of fragile X syndrome (FXS)-associated point mutations have been identified in the NTR, leading to the expression of mutated protein variants. Here, we show that the destabilizing effects of these mutations on the NTR region are less severe than those previously observed in the isolated domains, suggesting the presence of inter-domain interactions that stabilize the overall NTR architecture. Moreover, we demonstrate that the NTR structured region has an intrinsic propensity to undergo liquid-liquid phase separation (LLPS) and amyloid fibril formation in vitro, depending on protein concentration, and we characterize how three FXS-associated mutations (R138Q, G266E, and I304N) affect these processes. We show that the mutations either destabilize the entire NTR (G266E/I304N), markedly affect the kinetics of LLPS and suppress the droplet liquid nature (R138Q/G266E), or promote solid or gel-like non-amyloid aggregation (G266E), thus providing mechanistic insights into how they may alter protein function, contributing to the pathogenic mechanism. These findings suggest that the interplay between protein stability, LLPS, and fibrillization is finely regulated and may be critical for understanding FMRP function and its dysfunction in disease.

Indexed as

Fragile X Messenger Ribonucleoprotein 1Fragile X SyndromeMutationAmyloidHumansKineticsPhase SeparationProtein AggregatesProtein DomainsAmyloidFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1Protein Aggregatesamyloid fibrilsFragile X syndromeKH domainsliquid–liquid phase separation

Identifiers

PMID42068253
PMCPMC13669641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.